Notes in 13. Bedaquiline and 14. Pretomanid

To Subscribe, use this Key

Status	Last Update	Fields
Published	10/21/2024	The Bedaquiline inhibits {{c1::adenosine 5’ triphosphate (ATP) synthase}} in mycobacteria.
Published	10/21/2024	Has bacterial and sterilizing activity in the murine model of TB
Published	10/21/2024	Has in vitro activity against both replicating and nonreplicating bacilli
Published	10/21/2024	Bedaquiline is used in combination with at least {{c1::3}} other active medications
Published	10/21/2024	Bedaquiline's most common adverse effects{{c1::Nausea}}{{c2::Arthralgia}}{{c3::Headache}}
Published	10/21/2024	Bedaquiline is only used for {{c1::6}} months in guidelines and if the physician continues to use it, the physician should indicate {{c2::off label us…
Published	10/21/2024	Pretomanid is a new nitroimidazole that requires {{c1::chemical reduction}} to be active.
Published	10/21/2024	Pretomanid is used for treatment of drug-resistant tuberculosis in combination with other drugs {{c1:: linezolid, bedaquiline, and pretomanid combinat…
Published	10/21/2024	The Pretomanid has a regimen {{c1::BPaL/BPaLM}}
Published	10/21/2024	The pretomanid’s dosage is {{c1::200}} mg daily
Published	10/21/2024	The pretomanid’s adverse effects are{{c1::Headache}}{{c1::Gastrointestinal side effects}}{{c1::Elevated liver enzymes}}
Status	Last Update	Fields